CALGB-10403

1. 01

   MRD-negative remission does not settle the CR1 transplant decision, particularly with adverse genetics

2. 02

   Blinatumomab enthusiasm does not resolve which backbone to retain or how far to extrapolate E1910

   Sample finding · free

   A podcast speaker asked how blinatumomab could be incorporated into pediatric-inspired therapy and whether adding it benefits patients with MRD undetectable by next-generation sequencing.

   Source: podcast, 2024-12-22 · paraphrased; the full report links the source

3. 03

   MRD is discussed as an assay- and regimen-dependent trajectory, not a binary result

4. 04

   Maintaining asparaginase exposure requires distinguishing reactions, inactivation and safe switching

5. 05

   Exposure preservation has toxicity-specific limits: stopping, holding and rechallenging are not interchangeable

6. 06

   Age, obesity and formulation drive dosing questions, but observational risk is not proof of a modifiable survival effect

7. 07

   Adding blinatumomab is not the same CNS-risk question as replacing chemotherapy

8. 08

   Manageable bispecific toxicity still requires expertise, delivery support and selective withholding

9. 09

   Modified CALGB 10403 is described as feasible in Mexico and Guatemala, conditional on infrastructure and a learning curve

10. 10

    Access and AYA support determine which evidence-based choices are real options

11. 11

    Long-term CALGB 10403 discussion qualifies early optimism and keeps T-ALL distinct

12. 12

    Earlier CD19 targeting raises a relapse-phenotype question, not an established frontline CD19-loss rate

    Sample finding · free

    An audience member in a podcast panel asked about the frequency of CD19-negative relapse after frontline blinatumomab consolidation given during MRD-negative remission.

    Source: podcast, 2026-01-14 · paraphrased; the full report links the source

13. 13

    De-escalation, new delivery routes and CAR T are attractive, but their conditions remain explicit

The full report gives each finding its interpretation, the attributed views behind it, counterviews, limits and the verified claims with exact source passages.

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

Screened window

2021-09-14 → 2026-09-10

Cited window

2021-09-14 → 2026-09-10

Retrieved

2026-10-08

Title

An Intergroup Phase II Clinical Trial for Adolescents and Young Adults With Untreated Acute Lymphoblastic Leukemia (ALL)

Registry

NCT00558519

Study IDs

CALGB-10403 · ECOG C10403 · CDR0000574230 (NCI Physician Data Query)

Sponsor

Alliance for Clinical Trials in Oncology

Collaborators

National Cancer Institute (NCI)

Design

Phase 2 · interventional, na, single group, phase2

Status

Completed

Enrollment

318 actual

Start

2008-03-12 actual

Primary completion

2016-09 actual

Primary endpoint

Complete Response Rate

Interventions

11 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Sources were found by searching for the trial's name, registry number and known aliases. Discussion that refers to the trial without naming it may be missing.
• –20 points raised by the independent review are not yet resolved in this edition, such as a clinician view not yet captured as evidence or a qualifier to restore. The next refresh takes them up.
• –3 further source limits are recorded in the machine-readable scope of this record.
• –The material is not a representative sample of HCPs or all public discussion. Multiple versions of the same conversation do not increase the number of independent clinical opinions.
• –Three indexed podcast sources could not be read. Searches focused on trial identifiers and registry aliases may miss unnamed references, acronym variants or different transcription renderings.
• –An unclear treatment name prevents attributing one CNS-progression observation to a specific regimen; it is not used to claim a blinatumomab-specific finding.
• –Full text was unavailable for two linked publications. Their abstracts provide context but cannot independently resolve every detailed study assertion made by speakers.
• –No separate protocol document was available beyond registry material, and regulatory material covered only part of the intervention-related records. Speaker claims about approvals or guidelines remain attributed claims, not independent regulatory conclusions.
• –Many discussions concern age extensions, LBL, Ph-positive alternatives, post-transplant monitoring or research consolidation. Those settings are not treated as results or universal rules for the original CALGB 10403 population.
• –Some source names or professional roles are incompletely established. Identity context does not identify an otherwise unnamed passage or give a view additional evidentiary weight.
• –Posting dates do not establish when a session occurred or show that a clinician changed position across settings.

How reports are built and checked: Methods.

Last checked Oct 8, 2026. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

release 248afa050b6fd3a9af4e8672660f219a982be39d381bbd576c31b4cb02d8aef6

The same record as JSON or Markdown, or through the Erudio MCP server.

curl https://www.erudio.com/reports/calgb-10403-nct00558519.json
curl https://www.erudio.com/reports/calgb-10403-nct00558519.md

# MCP (https://mcp.erudio.com/mcp)
get_report_card({ "slug": "calgb-10403-00558519" })